Trial Information

Summary: Clinical Study of Schizophrenia.

Summary:

The objective of this study is to compare the effectiveness of a marketed drug to placebo in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Inclusion Criteria: (a subject must meet the following criteria in order to be eligible for this study)

• If female must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
• Diagnosis of Schizophrenia
• Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.

Exclusion Criteria: (subjects cannot meet any of the following criteria in order to be considered eligible for this study)

• Patients who are currently taking or have taken antidepressant medication in the last month prior.
• Patients who are or have been suicidal or homicidal in the last 6 months.
• Patients with a history of autistic disorder or another pervasive developmental disorder
• Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition

Gender: Both

Minimum Age: 18 Years

Maximum Age: 65 Years

Please click here for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:59 AM